Mar 07, 2017
BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility    read more...
Mar 02, 2017
BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111    read more...
Mar 02, 2017
BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting    read more...
Feb 27, 2017
BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference    read more...
Feb 08, 2017
BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference    read more...
Jan 25, 2017
BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia    read more...
Dec 30, 2016
BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317    read more...
Dec 21, 2016
BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290    read more...
Dec 05, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenström’s Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting    read more...
Dec 05, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting    read more...
Nov 23, 2016
BeiGene Announces Closing of $200 Million Public Offering    read more...
Nov 17, 2016
BeiGene Announces Pricing of $200 Million Public Offering    read more...
Nov 16, 2016
BeiGene Announces Proposed Public Offering    read more...
Nov 11, 2016
BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting    read more...
Nov 10, 2016
BeiGene Reports Third Quarter 2016 Financial Results    read more...
Nov 03, 2016
BeiGene Announces Oral Presentations on BTK Inhibitor BGB-3111 at the 2016 American Society of Hematology Annual Meeting    read more...
Nov 01, 2016
BeiGene to Participate in 25th Annual Credit Suisse Healthcare Conference    read more...
Oct 07, 2016
BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenstrom’s Macroglobulinemia at 9th International Workshop on Waldenstrom’s Macroglobulinemia    read more...
Oct 04, 2016
BeiGene to Host Conference Call on BGB-3111 Data Presentation at IWWM-9    read more...
Oct 03, 2016
BeiGene Appoints Ross Pettit as Senior Vice President, Global Development Operations    read more...